Bloomage BioTech CEO eyes takeovers

Xuekun Jin, chief executive of the Hong Kong-listed Chinese company, talks to FinanceAsia about his plans.

Bloomage BioTech CEO eyes takeovers

Chinese cosmetics and biomedical company Bloomage BioTech, is on the lookout for acquisitions, chief executive Xuekun Jin told FinanceAsia on Thursday.

The Hong Kong-listed corporation has acquired two European businesses already, paying 59 million $63.7 million for French cosmetic device maker Vivacy in 2015 and 25.15 million for Revitacare, another French manufacturer, in January. But Jin is eager to gobble up more overseas rivals.

“We have some targets, and we’re...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: bloomage biotechnology | china | acquisitions | ecm | consumer | gic

Print Edition

FinanceAsia Print Edition